Embeconazole

Drug Profile

Embeconazole

Alternative Names: CS 758; R 120758

Latest Information Update: 13 May 2008

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antifungals; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Mycoses

Most Recent Events

  • 13 May 2008 Phase I development is ongoing
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 31 Mar 2006 Phase-I clinical trials in Mycoses in European Union (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top